Back to search results

Study of NY-ESO-1 TCR/IL-15 NK for Advanced Sarcomas

This study is testing a new treatment called NY-ESO-1 TCR/IL-15 NK, given along with chemotherapy drugs (Fludarabine phosphate and Cyclophosphamide), for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. The main goal is to find a safe and effective dose of NY-ESO-1 TCR/IL-15 NK. Researchers will also look at how well this treatment shrinks tumors. You might be able to join if you are between 16 and 80 years old, and your tumor has a specific biomarker (NY-ESO-1) and a certain genetic marker (HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06). The study is currently recruiting 44 participants, but its overall status is unclear.

Study design
This is an interventional study planning to enroll 44 participants. It aims to find the optimal dose and safety of the treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06083883

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Recruiting
PHASE1Ages 16–80InterventionalTreatment
M.D. Anderson Cancer Center
~44 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Fludarabine phosphateNY-ESO-1 TCR/IL-15 NKCyclophosphamide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over Through study completion; an average of 1 year.

Conditions

Synovial Sarcoma
Myxoid/Round Cell Liposarcoma

Explore related trials

Myxoid LiposarcomaSolid NeoplasmSynovial SarcomaCancer/Testis Antigen 1HLA-A Gene

NCT06083883

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • John Livingston, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

John Livingston, MD
[email protected]
(713) 792-3626
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

New York Heart Association Class III or IV heart failure
Myocardial infarction or stroke ≤ 26 weeks prior to NY-ESO-1 TCR/IL-15 NK cell infusion
Unstable angina within ≤ 13 weeks prior to NY-ESO-1 TCR/IL-15 NK cell infusion unless the underlying disease has been corrected by procedural intervention (e.g., stent, bypass)
Severe aortic stenosis.
Uncontrolled arrhythmia, considered per PI evaluation.
Congenital long QT syndrome.

What this trial measures

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion; an average of 1 year.